Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.66−0.30 (-0.78%)
Close on Nov 20, 2026Market cap $27.92BP/E –Yield –
Roivant Sciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Roivant Sciences's free cash flow for the twelve months ending Jun 30, 2026 was -$821.06M. For fiscal 2025 it was -$758.56M. The highest annual figure on record is -$557.94M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | -$758.56M | – |
| FY2024 | Mar 31, 2025 | -$844.05M | – |
| FY2023 | Mar 31, 2024 | -$766.65M | – |
| FY2022 | Mar 31, 2023 | -$856.08M | – |
| FY2021 | Mar 31, 2022 | -$695.17M | – |
| FY2020 | Mar 31, 2021 | -$557.94M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | -$270.92M | – |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | -$165.08M | – |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | -$191.55M | – |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | -$193.51M | – |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | -$208.42M | – |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | -$173.38M | – |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | -$209.08M | – |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | -$267.80M | – |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | -$193.79M | – |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | -$108.81M | – |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | -$210.81M | – |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | -$196.70M | – |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | -$250.34M | – |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | -$180.71M | – |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | -$223.10M | – |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | -$192.73M | – |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | -$259.54M | – |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | -$153.73M | – |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | -$274.57M | – |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | -$123.36M | – |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | -$143.51M | – |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | -$110.16M | – |
| Q3 FY2020CQ4 2020 | Dec 31, 2020 | -$236.97M | – |
| Q2 FY2020CQ3 2020 | Sep 30, 2020 | -$99.35M | – |
| Q1 FY2020CQ2 2020 | Jun 30, 2020 | -$111.47M | – |
See a number that looks wrong?